+ Filter
Loading...
Custom Services order now ship next day

Anti-ROR1 Recombinant Antibody Products

Loading...

Anti-ROR1 Products

More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs provides precision-engineered anti-ROR1 recombinant antibodies to support biomedical investigations across therapeutic and mechanistic studies. Leveraging proprietary antibody engineering technologies, these biologics demonstrate exceptional sensitivity and low cross-reactivity, validated through orthogonal experimental approaches. Their robust performance in applications spanning cellular phenotyping, signaling pathway analysis, and therapeutic target validation establishes them as critical tools for preclinical research.

ROR1: A Promising Target for Cancer Therapy

The receptor tyrosine kinase ROR1, a critical regulator of embryogenesis, exhibits marked overexpression across multiple malignancies. Experimental evidence indicates its oncogenic contributions occur through activation of survival signaling mechanisms, principally via non-canonical WNT5A-mediated cascades. Therapeutic antibodies targeting ROR1 have demonstrated preclinical efficacy and early clinical potential, positioning this receptor as an attractive therapeutic target in oncology.

Alternative Names

Tyrosine-protein kinase transmembrane receptor; receptor tyrosine kinase like orphan receptor 1; receptor tyrosine kinase-like orphan receptor 1; ROR1; NTRKR1; dJ537F10.1.

Background

This gene encodes a receptor tyrosine kinase-like orphan receptor that modulates neurite growth in the central nervous system. The encoded protein is a glycosylated type I membrane protein that belongs to the ROR subfamily of cell surface receptors. It is a pseudokinase that lacks catalytic activity and may interact with the non-canonical Wnt signalling pathway. This gene is highly expressed during early embryonic development but expressed at very low levels in adult tissues. Increased expression of this gene is associated with B-cell chronic lymphocytic leukaemia. Alternative splicing results in multiple transcript variants encoding different isoforms.

Protein class

Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Cell type enhanced (Oligodendrocytes, Astrocytes, Inhibitory neurons, Alveolar cells type 1, Microglial cells)

Immune cell specificity

Not detected in immune cells

Cell line specificity

Cell line enhanced (ASC diff, ASC TERT1, CACO-2, HHSteC, HSkMC, NTERA-2)

Molecular function

Kinase, Receptor, Transferase

More Types Infomation

Anti-ROR1 rAb Products

Creative Biolabs develops functionally optimized recombinant antibodies targeting ROR1, designed to achieve high binding affinity and selective specificity. The modular configurations facilitate applications in immune system characterization, cancer biology research, and the screening of therapeutic candidates. Manufacturing processes incorporate structured quality assurance protocols, verified through complementary analytical techniques such as conformational epitope analysis and ligand-binding assays. Through the integration of structural optimization and standardized production protocols, these biologics demonstrate improved target selectivity, binding kinetics, and batch-to-batch consistency—thereby increasing reliability in both fundamental research and therapeutic development scenarios.

Table 1. Featured anti-ROR1 recombinant antibody products at Creative Biolabs.

Cat. No. Product Name Target Species Host Species Applications
ZG-071R Mouse Anti-ROR1 Recombinant Antibody (ZG-071R) Human Mouse IgG WB, ELISA, IF
HPAB-0569LY-S(P) Human Anti-ROR1 Recombinant Antibody scFv Fragment (HPAB-0569LY-S(P)) Human, Mouse Human scfv ELISA, RIA, FC, Inhib, WB
HPAB-0181-LSX Human Anti-ROR1 Recombinant Antibody (HPAB-0181-LSX) Human Human IgG1 ELISA, FC, IF, IHC, WB
HPAB-0175-LSX Human Anti-ROR1 Recombinant Antibody (HPAB-0175-LSX) Human Human IgG1 ELISA, SPR, FC, ADCC, CDC, FuncS
HPAB-0176-LSX Human Anti-ROR1 Recombinant Antibody (HPAB-0176-LSX) Human Human IgG1 SPR, FC, ELISA, Cyt, Apop

Creative Quality Control

Creative Biolabs implements a multi-tiered quality control framework to develop recombinant antibodies targeting ROR1, achieving enhanced target specificity and favorable binding kinetics through iterative optimization processes. Systematic functional characterization of these biologics confirms reliable performance metrics across in vitro assays, ex vivo models, and preclinical studies, with batch-to-batch reproducibility validated through orthogonal analytical techniques. This methodological rigor positions the antibodies as critical reagents for molecular interrogation of ROR1-mediated signaling pathways in oncology and regenerative medicine research.

Fig.1 WB analysis. (Creative Biolabs Original)Fig.1 WB analysis of anti-ROR1 antibody
(Cat# ZG-071R, Creative Biolabs).

Fig.2 IF analysis. (Creative Biolabs Original)Fig.2 IF analysis of anti-ROR1 antibody
(Cat# ZG-071R, Creative Biolabs).

Fig.3 SDS-PAGE analysis. (Creative Biolabs Original)Fig.3 SDS-PAGE analysis of anti-ROR1 antibody
(Cat# HPAB-0569LY-S(P), Creative Biolabs).

Fig.4 ELISA analysis. (Creative Biolabs Original)Fig.4 ELISA analysis of anti-ROR1 antibody
(Cat# HPAB-0569LY-S(P), Creative Biolabs).

Fig.5 SDS-PAGE analysis. (Creative Biolabs Original)Fig.5 SDS-PAGE analysis of anti-ROR1 antibody
(Cat# HPAB-0181-LSX, Creative Biolabs).

Fig.6 HPLC analysis. (Creative Biolabs Original)Fig.6 HPLC analysis of anti-ROR1 antibody
(Cat# HPAB-0176-LSX, Creative Biolabs).

Customer Reviews

Excellent
Re***n
Human Anti-ROR1 Recombinant Antibody (HPAB-AP786-YC) (HPAB-AP786-YC)
The ROR1 antibody from Creative Biolabs showed excellent specificity in our flow cytometry experiments. We observed minimal off-target binding, which was crucial for our analysis.
21/May/2023
Excellent
Xi***u
Mouse Anti-ROR1 Recombinant Antibody (HPAB-673-FY) (HPAB-673-FY)
We were very satisfied with the consistency and performance of the ROR1 recombinant antibody. It worked well in our preclinical studies, providing reliable and reproducible data.
22/Sep/2024
Excellent
Da***n
Human Anti-ROR1 Recombinant Antibody (HPAB-0179-LSX) (CAT#: HPAB-0179-LSX)
Creative Biolabs offered a great selection of ROR1 antibodies. We found one that perfectly matched our research needs, and the technical support was very helpful throughout the ordering process.
13/Feb/2025

rAb Production

Creative Biolabs serves as a reliable global collaborator, providing a steady and trustworthy supply of high-quality anti-ROR1 recombinant antibodies to researchers across the globe. Utilizing advanced recombinant technology, our antibodies undergo thorough development and validation processes to ensure outstanding quality and effectiveness across various research applications. Our dedication lies in facilitating scientific advancement by equipping researchers with dependable tools essential for investigating the intricacies of ROR1 signaling across diverse biological scenarios.

Featured Anti-ROR1 Recombinant Antibody Production PlatformsFig.7 Milligram-scale. (Creative Biolabs Original)
Fig.7 Milligram-scale anti-ROR1 recombinant antibody production.

Fig.8 Gram-scale. (Creative Biolabs Original)Fig.8 Gram-scale anti-ROR1 recombinant antibody production.

rAb Modalities

Creative Biolabs provides premium, customizable anti-ROR1 recombinant antibodies designed to address particular research requirements. These antibodies are available in multiple formats and are carefully designed to address the distinct requirements of research communities at local, national, and global levels.

Fig.9 ROR1 antibody production and modalities. (Creative Biolabs Original)Fig.9 Full-length anti-ROR1 recombinant antibody production and modalities.

ROR1-Targeted Drug Information

Table 2. Public drug targeting ROR1.

Company Research phase Classification Condition
Oncternal Therapeutics
University of California, San Diego (Originator)
Phase III Cancer Immunotherapy
Humanized Monoclonal Antibodies
B-cell chronic lymphocytic leukemia
Cancer, breast
Cancer, prostate (castration-resistant), metastatic
Chronic lymphocytic leukemia
Lymphoma, mantle cell
Lymphoma, marginal zone
Lymphoma, small lymphocytic
Merck & Co (Originator)
Merck & Co. (Merck & Co)
VelosBio (Merck & Co)
VelosBio (Merck & Co)
Phase II/III Antibody-Drug Conjugates (ADCs)
Auristatins
Cancer Immunotherapy
Humanized Monoclonal Antibodies
Oligopeptides, less than 10 AA
B-cell acute lymphocytic leukemia
Cancer, bladder (urothelial carcinoma)
Cancer, breast
Cancer, lung (non-small cell) (NSCLC), metastatic
Cancer, ovary
Cancer, pancreas
Cancer, solid tumor
Cancer, stomach
Chronic lymphocytic leukemia
Hematologic-blood cancer
Lymphoma
Lymphoma, Burkitt
Lymphoma, diffuse large B-cell
Lymphoma, follicular
Lymphoma, mantle cell
Lymphoma, marginal zone
Neuroblastoma
Non-Hodgkin lymphoma
Richter's syndrome
Sarcoma, Ewing
Triple negative breast cancer
People's Liberation Army of China (Originator)
Zhejiang University (Originator)
Phase I/II Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells)
Cancer, solid tumor
Lymphoma, diffuse large B-cell
Oncternal Therapeutics (Originator) Phase I/II Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells)
Lymphoma, B-cell
Lymphoma, diffuse large B-cell
Lymphoma, follicular
Lymphoma, mantle cell
Lymphoma, primary mediastinal large B-cell
Richter's syndrome
Biokin Pharmaceutical (Originator)
SystImmune
SystImmune (Originator)
Phase I/II Cancer Immunotherapy
Multispecific Antibodies
Acute myeloid leukemia
B-cell acute lymphocytic leukemia
Cancer, breast
Cancer, solid tumor
Chronic lymphocytic leukemia
Hematologic-blood cancer
Lymphoma, small lymphocytic
Non-Hodgkin lymphoma
NovalGen (Originator)
University College London (Originator)
Phase I/II Bispecific Antibodies
Cancer Immunotherapy
Fusion Proteins
Humanized Monoclonal Antibodies
Polypeptides, from 41 AA
Single-Chain V-Domain Antibody Fragment (scFv)
Cancer
Chronic lymphocytic leukemia
Hematologic-blood cancer
Lymphoma, mantle cell
Lymphoma, small lymphocytic
NBE-Therapeutics (Originator)
Scripps Research (Originator)
Phase I/II Anthracyclines
Antibodies
Antibody-Drug Conjugates (ADCs)
Cancer Immunotherapy
Oligopeptides, less than 10 AA
Cancer, solid tumor
Triple negative breast cancer
Pure Biologics (Originator) Phase I Cancer Immunotherapy
Human Monoclonal Antibodies
Cancer, head and neck (squamous cell carcinoma)
Cancer, solid tumor
Chronic lymphocytic leukemia
Hematologic-blood cancer
Soft tissue sarcoma
Triple negative breast cancer
EpimAb Biotherapeutics (Originator) Phase I Bispecific Antibodies
Cancer Immunotherapy
Cancer, solid tumor
Numab Therapeutics (Originator) Phase I Cancer Immunotherapy
Fusion Proteins
Polypeptides, from 41 AA
Single-Chain V-Domain Antibody Fragment (scFv)
Trispecific Antibodies
Cancer, solid tumor
Lyell Immunopharma (Originator) Phase I Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells)
Cancer, endometrium
Cancer, lung (non-small cell) (NSCLC)
Cancer, ovary
Cancer, solid tumor
Chronic lymphocytic leukemia
Multiple myeloma
Triple negative breast cancer

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Leveraging our vast knowledge and years of remarkable experience in antibody creation and manufacturing, Creative Biolabs provides ROR1 recombinant antibodies that regularly show exceptional performance throughout a broad range of research uses. We are confident in the quality and reliability of our antibodies and encourage researchers interested in exploring the potential of ROR1 to get in touch with us directly to receive exclusive pricing details tailored to their specific needs.

Go to compare

Go to compare